Fate Therapeutics, Inc.
FATE
$1.12
$0.010.90%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -31.23% | 105.85% | -78.55% | -87.34% | -89.67% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -31.23% | 105.85% | -78.55% | -87.34% | -89.67% |
| Cost of Revenue | -3.76% | -30.34% | -43.28% | -61.21% | -67.81% |
| Gross Profit | -0.71% | 37.87% | 19.35% | 38.41% | 50.90% |
| SG&A Expenses | -13.99% | -12.75% | -6.42% | 8.41% | 3.07% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -10.45% | -9.29% | -17.66% | -32.91% | -42.47% |
| Operating Income | 9.14% | 12.79% | -2.64% | 4.96% | 19.20% |
| Income Before Tax | 2.39% | 7.46% | -15.74% | -2.92% | 16.94% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 2.39% | 7.46% | -15.74% | -2.92% | 16.94% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2.39% | 7.46% | -15.74% | -2.92% | 16.94% |
| EBIT | 9.14% | 12.79% | -2.64% | 4.96% | 19.20% |
| EBITDA | 8.35% | 13.29% | -2.52% | 5.86% | 21.72% |
| EPS Basic | 14.93% | 22.13% | -0.92% | 6.37% | 21.30% |
| Normalized Basic EPS | 24.54% | 32.21% | 12.14% | 6.03% | 20.77% |
| EPS Diluted | 14.93% | 22.13% | -0.92% | 6.40% | 21.32% |
| Normalized Diluted EPS | 24.54% | 32.21% | 12.14% | 6.03% | 20.77% |
| Average Basic Shares Outstanding | 13.64% | 18.84% | 15.37% | 10.89% | 6.41% |
| Average Diluted Shares Outstanding | 13.64% | 18.84% | 15.37% | 10.89% | 6.41% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |